New vaccine strategy could shield spleenless patients from deadly infection

NCT ID NCT04166656

Recruiting now Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing three different ways to give the meningococcal B vaccine to adults who have had their spleen removed. People without a spleen are at higher risk for serious infections. The study will compare how well each vaccine schedule triggers the immune system and how safe they are, with the goal of finding the best protection strategy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trumenba® and Bexsero® (meningococcal B vaccines)
What this could lead to: If successful, this could identify the most effective vaccine schedule to protect people without a spleen from a life-threatening meningococcal infection.
What could go wrong: This is a relatively small trial (84 participants) and focuses on immune response, not directly on preventing infection. Results may not apply to all asplenic patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASPLENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial isolated congenital asplenia meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SPLENECTOMY

Contacts and locations

Locations

I-REIVAC/CIC1417 Cochin Hospital, AP-HP
RECRUITING

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.